Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
Company Research
Source: GlobeNewswire
CUPERTINO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present new pharmacology data on brilaroxazine as part of two poster presentations at the ASPET 2024 Annual Meeting, to be held in Arlington, VA May 16-19, 2024. Details for the poster presentation can be found below: Title: Brilaroxazine Displays Limited Interaction with Clinically Relevant Drug TransportersPoster Board: 806Abstract Number: 129049Room: Independence AB (Independence Level)Date: Sunday, May 19, 2024Time: 5:15 – 7:15pm ETPresenter: Laxminarayan Bhat, Reviva PharmaceuticalsLocation: Hyatt Regency Crystal City, Arlington, VA Title: Absorption, Metaboli
Show less
Read more
Impact Snapshot
Event Time:
RVPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVPH alerts
High impacting Reviva Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
RVPH
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH Accesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHPR Newswire
- Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH GlobeNewswire
- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $17.00 price target on the stock.MarketBeat
RVPH
Earnings
- 11/14/23 - Miss
RVPH
Sec Filings
- 5/31/24 - Form SC
- 5/29/24 - Form 8-K
- 5/29/24 - Form 424B5
- RVPH's page on the SEC website